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1. Introduction 
Interleukin-12 (IL-12) is a heterodimeric pro-inflammatory cytokine long recognized to have 
properties capable of mediating immune effector functions in a manner compatible to 
enhancing endogenous anti-tumor immune responses. For this reason the cytokine has 
garnered significant interest from investigators in the field of immune mediated anti-cancer 
therapies. While the exact mechanisms whereby IL-12 mediates pro-inflammatory 
endogenous anti-tumor responses remains to be fully elucidated, pre-clinical murine tumor 
models demonstrate unequivocal anti-tumor benefit mediated by IL-12 (1-5). Preclinical 
studies demonstrate that the mechanisms of IL-12 mediated anti-tumor endogenous 
immune responses seen in these models are likely to be complex and multifactorial. Beyond 
the ability of IL-12 to induce an inflammatory Th1 CD4+ T cell response, studies have 
demonstrated the ability of IL-12 to enhance CD8+ T cell cytoxicity. Additionally, preclinical 
studies have shown IL-12 to recruit and activate innate cytotoxic NK cells and modulate a 
pro-inflammatory macrophage phenotype. Further, studies have shown that T cell secretion 
of IFN┛ mediated by IL-12 may reverse T cell anergy and confer effector T cell resistance to 
immune suppressive Tregs. The ability of IL-12 to activate the adaptive as well as the innate 
immune systems, but also further modulate the otherwise immune-hostile tumor 
microenvironment, suggests that the cytokine may serve as a potent immunotherapeutic 
agent. Significantly, pre-clinical murine tumor models have largely validated these 
predictions. These promising pre-clinical studies consequently spurred on a series of clinical 
trials treating patients with a variety of tumors with intravenous infusions of recombinant 
IL-12. Unfortunately, these studies have yielded only modest tumor responses in the context 
of associated severe and unforeseen toxicities. The IL-12 related toxicities seen in these early 
clinical trials served to markedly dampen enthusiasm for this cytokine as a potential anti-
tumor therapeutic reagent in the clinical setting. However, subsequent clinical trials 
conducted utilizing direct infusion of IL-12 into accessible tumor sites has resulted in 
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promising anti-tumor responses in the absence of toxicities induced by systemic infusion 
seen in earlier studies. Thus, based on these clinical trials, the potent anti-tumor effects of IL-
12 can best be harnessed by restricting its administration directly into the tumor 
microenvironment. Therefore, optimal utilization of the anti-tumor efficacy of IL-12 may be 
realized utilizing novel approaches whereby the cytokine is delivered directly to the site of 
the tumor with limited systemic distribution to avoid previously observed toxicities. In this 
chapter, we review the biology of IL-12 and the predicted mechanisms whereby this 
cytokine may mediate anti-tumor endogenous immune responses. We further discuss pre-
clinical studies to support the utilization of IL-12 in cancer therapy as well as clinical trial 
data, which, in part, have tempered enthusiasm for IL-12 as an effective anti-tumor reagent 
in the clinical setting due to associated toxicities. Finally, we present and discuss previously 
published approaches to overcome systemic toxicity through targeted delivery of IL-12 
directly into the tumor microenvironment. 
2. Basic biology and immune stimulatory effects of IL-12 
IL-12 is biologically functional as a heterodimeric molecule consisting of an ┙ and ┚ chain, 
where covalently-linked p35 and p40 subunits together form the active molecule, IL-12p70 
(6-8). The p35 subunit is expressed ubiquitously but only phagocytic cells produce the p40 
subunit, therefore functional IL-12p70 is only produced by activated antigen-presenting 
cells (APCs), neutrophils and macrophages (9). The IL-12 receptor (IL-12R) is composed of 
two subunits, 1 and 2, and is expressed predominantly on dendritic cells (DCs), T cells 
and natural killer (NK) cells. The IL-12R mediates signal transduction through the Janus 
kinases (JAKs) but these pathways will not be discussed here (10).  
Initially, IL-12 was described as “Natural killer-stimulating factor” and “cytotoxic 
lymphocyte maturation factor” and has since been reported to have important effects on the 
generation of an adaptive immune response (6, 11). It is a potent activator of NK cells, with 
IL-12 stimulation resulting in enhanced NK cell mediated cytotoxicity (9). The effects of IL-
12 on T cells include enhanced cytotoxicity and CD4+ T cell differentiation into type-1 helper 
T cells (Th1) (12-14). It has also been demonstrated that IL-12 could provide “signal 3” for T 
cell activation, where signal 2 provides co-stimulation and signal 3 upregulates the 
expression of the lytic protein Granzyme B, leading to increased cytotoxic effector function 
and overcoming tolerance (15, 16). IL-12 also mediates significant effects on T cell 
proliferation. In a murine model of adoptive transfer, OT-1 T cells were inoculated into an 
irradiated syngeneic mouse and exhibited increased homeostatic proliferation when 
supported with injection of IL-12 (17). Further studies have demonstrated that T cell 
expansion was augmented with IL-12 as a result of decreased apoptosis. This was found to 
be due to decreased Fas expression, increased expression of anti-apoptotic FLIP proteins 
and inhibition of caspase activation (18). Additionally, it has been reported that IL-12 is 
important in the fate of CD8+ T cells where IL-12 promotes differentiation into functional 
effector cells and inhibits memory T cell formation (19). 
An additional, but no less important outcome following IL-12 production is the induction of 
Interferon (IFN)-from B, T and NK cells (20-22). IL-12 has positive feedback loops whereby 
IL-12 stimulates DCs to produce more IL-12, thereby stimulating IFN production resulting 
in additional IL-12 produced by monocytes (23, 24). This IFN is able to further activate 
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innate and adaptive immune systems as well as influencing the tumor microenvironment, as 
discussed below. Many of these IL-12 mediated anti-tumor effects are abrogated upon 
neutralization of IFN thereby demonstrating the importance of this pro-inflammatory 
cytokine in IL-12 mediated immune stimulation (3, 4, 25). 
3. IL-12 in the tumor microenvironment 
The wide-ranging effects of IL-12 have profound impacts upon the tumor 
microenvironment; acting directly on tumor cells, influencing the surrounding tumor 
stroma/structure, and modulating infiltrating immune cells. These effects, detailed below, 
mediate the recruitment of lymphocytes, activation of tumor infiltrating lymphocytes, as 
well as direct effects on tumor cells to decrease angiogenesis which combine to result in 
tumor eradication or inhibition.  
Direct effects of IL-12 on tumor cells may include the ability of IL-12 to up-regulate 
expression of molecules that induce immune recognition and death of tumor cells. It has 
been documented that adenoviral mediated expression of IL-12 in human osteosarcoma cells 
or chemo-resistant breast cancer cells increased expression of Fas, and subsequent apoptosis 
of tumor cells (26). This was postulated to be a function of the IL-12R 1 chain activating 
NF-B, a signaling effect that is thought to be absent in lymphocytes ensuring that IL-12 
stimulation of T and NK cells does not result in Fas up-regulation or apoptosis. In a mouse 
model of mammary adenocarcinoma, it was demonstrated that IL-12 induced IFN led to 
increased surface MHC expression on tumor cells (2), increasing the presentation of tumor-
associated antigens to the immune system and resulting in increased edogenous anti-tumor 
immune responses.  
IL-12 is widely reported to increase IFN expression, which is responsible for mediating 
effects directly on the tumor cells, including upregulation of inducible nitric oxide synthase 
(iNOS) and indolamine 2,3-dioxygenase (IDO) genes, as well as increased MHC expression. 
Utilizing a murine model of fibrosarcoma, systemic injection of IL-12 was found to induce 
IFN, which in turn mediated increased expression of IDO and iNOS mRNA by tumor cells 
(3). The products of these genes may slow the growth of tumor cells. IDO is thought to 
influence tumor growth through the deprivation of tryptophan (27). This was also 
demonstrated in a study employing a murine model of spontaneous breast cancer treated 
with systemic IL-12 injection (1).  
An important tumor microenvironment modulatory effect by IL-12 is the inhibition of 
angiogenesis. Folkman and others have elegantly demonstrated the anti-angiogenic role of 
IL-12 against fibroblast growth factor-induced corneal neo-vascularization. This effect was 
abrogated upon neutralization of IFN-┛ and a downstream effector, IP-10, implicating the 
latter as the mediator of this effect (28-31). IL-12 has further been shown to mediate down-
regulation of pro-angiogenic gene vascular endothelial growth factor (VEGF)-C, as well as 
the pro-angiogenic proteins, VEGF and basic fibroblast growth factor (BFGF) on tumor cells 
and supporting fibroblast cells (32, 33). There is also evidence to suggest that NK cells and 
CD8+ T cells may contribute to the IL-12 mediated anti-angiogenic effect in some models (34, 
35). Cytotoxic T and NK cells were shown to directly lyse epithelial cells, therefore 
contributing to inhibition of neo-vascularization. It is likely that both secreted factors, such 
as IP-10 from fibroblasts, as well as direct effects mediated by T and NK cells contribute to 
the overall anti-angiogenic effects of IL-12.  
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IL-12 may directly increase the expression of lymphocyte adhesion molecules within 
tumors, thereby increasing the infiltration of immune effectors into the tumor. For example, 
treatment of a poorly immunogeneic mammary adenocarcinoma with IL-12 resulted in 
increased vascular cell adhesion molecule (VCAM)-1 expression within tumors (2). This 
result was also reported in a murine model of breast cancer (1). In addition, a recent report 
documented IL-12 mediated activation of lympoid-tissue inducer (LTi) cells, which led to 
the up-regulation of adhesion molecules and increased leukocyte infiltration (36). Utilizing a 
murine model of melanoma, it was found that LTi cells expressing the NK cell receptor 
NKp46, were responsible for up-regulating both VCAM-1 and inter-cellular adhesion 
molecule (ICAM)-1 within the tumor microenvironment. Up-regulated expression of 
VCAM-1 has been demonstrated to increase the migration of lymphocytes, therefore 
allowing  increased lymphocytic infiltration into IL-12 treated tumors (37).  
A consequence of increased expression of adhesion molecules is the increased infiltration of 
tumors with immune effector cells, as reported in several studies wherein solid tumors were 
treated with IL-12. In murine models of mammary adenocarcinoma, lung alveolar 
carcinoma, fibrosarcoma and spontaneous breast cancer, tumor masses were infiltrated with 
lymphocytes following systemic IL-12 treatment (1-4, 25, 38). Infiltrating cells were NK cells, 
CD8+ T cells, CD4+ T cells, and macrophages, depending on the model utilized. Infiltration 
of lymphocytes is highly important for IL-12 mediated tumor regression, as depletion of 
CD4 or CD8 T cells prior to treatment abrogated the anti-tumor response in several murine 
models (2, 4, 5).  
IL-12 has further been shown to mediate activation of tumor infiltrating lymphocytes (TILs). 
In the context of minimal residual disease following transplant in a murine model of 
lymphoma, IL-12 treatment was shown to activate splenocytes, as noted by up-regulation of 
CD25 (39). Subsequent studies have demonstrated that IL-12 therapy mediates substantial 
increase in Granzyme B expression, increased proportion of IFN secreting CD8+ T cells, and 
greater levels of IFN secretion in previously quiescent tumor infiltrating CD8+ T cells (38). 
A recent report has identified the specificity of endogenous T cells activated by IL-12 in a 
murine model of melanoma (40). This study demonstrated that IL-12 therapy stimulated a 
protective CD8+ T cell response, where T cells were specific for multiple tumor associated 
stromal antigens. Other cells activated in response to IL-12 include B cells, as demonstrated 
by an increase in tumor-reactive antibodies following IL-12 treatment (2). However, the 
clinical relevance of these tumor reactive antibodies currently remain unclear.  
IL-12 may reverse the anergic state of T cells present within the tumor microenvironment. In 
elegant studies, primary human lung biopsy samples were transplanted into SCID mice and 
treated with intra-tumoral injection of IL-12 microbeads (41-43). IL-12 therapy was found to 
mediate regression of tumors, which was dependent on the reactivation of CD4+ T cells 
within the tumor. These cells were stimulated to proliferate, secrete IFNand mediate 
complete eradication of the tumor. Additionally, anergy induced in murine CD4+ T cells by 
regulatory T cells can be overcome with the addition of IL-12 (44). The authors demonstrate 
that IL-12 mediates effects on the CD4+ effector T cell allowing proliferation and IFN 
secretion despite the presence of suppressive Tregs. 
IL-12 has further been demonstrated to impact regulatory cell populations present in the 
tumor microenvironment. Using a murine model of lung carcinoma, it was demonstrated 
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that IL-12 microsphere therapy resulted in a reduction of CD4+ CD25+ suppressor T cells 
(38). This study reported an IFN dependent induction of apoptosis in the suppressive T cell 
subset. Relieving tumor resident T cells of suppressive factors may allow the generation of 
effective endogenous anti-tumor responses. Recent reports have demonstrated that IL-12 
can also inhibit the expansion of regulatory T cells (45). IL-12 was found to inhibit the 
expansion of Tregs in vitro and in vivo in a murine model of lymphoma. Inhibition of Treg 
expansion was shown to occur in a IFN dependent fashion as IL-12 did not effect Treg 
expansion in IFN receptor deficient mice.  
Tumor-associated macrophages (TAMs) play a major role in promoting tumor growth and 
metastasis and in suppressing the antitumor immune response. Such local immune 
dysfunction is recognized as one of the major barriers to cancer immunotherapy (46). 
Macrophages are also functionally plastic, meaning that they can convert between 
functional states (47). In particular, it has been reported that TAMs can be converted from a 
M2 suppressive phenotype to an M1 inflammatory phenotype following treatment of 
tumor-bearing mice with IL-12 containing microspheres (48, 49). Moreover, tumor lesions 
treated with tumor targeted T cells engineered to secrete IL-12 were infiltrated with 
activated M1 type of macrophages that were not found in tumors upon T cell therapy 
without IL-12. The accumulation of activated macrophages was critical to the antitumor 
immune response as depletion of these macrophages abolished the anti-tumor response (50). 
4. Preclinical studies investigating the anti-tumor therapeutic potential of IL-12 
Early studies investigating the utilization of IL-12 as an anti-cancer therapeutic agent 
provided encouraging results, conveying the anti-tumor potential of this powerful cytokine. 
Intra-tumoral and systemic administration of this cytokine demonstrated marked tumor 
regression in several murine models of cancer. These include a poorly immunogenic 
mammary adenocarcinoma, lung alveolar carcinoma, fibrosaroma, spontaneous breast 
cancer, ovarian carcinoma, lymphoma, renal cell carcinoma, as well as a model of 
pulmonary metastasis of melanoma (1-5, 38, 39, 51). IL-12 was shown to mediate disease 
eradication in primary tumors, as well as eradication of metastasis following surgical 
removal of primary tumors (2). Additionally, using a murine model of minimal residual 
lymphoma disease following transplant, IL-12 was shown to eradicate disease following 
transplant without affecting lympho-hematopoietic recovery (39). Significantly, IL-12 exerts 
anti-tumor effects and mediates tumor regression in models of early, intermediate and late 
stage disease, illustrating the efficacy of IL-12 anti-cancer therapy even in the setting of 
advanced disease (51). These studies provided rational for the use of this cytokine in cancer 
therapy and several clinical approaches to utilize IL-12 in cancer therapy have been 
developed as discussed below. 
Other therapeutic strategies to deliver IL-12 to the tumor microenvironment include the 
sustained release of cytokine using nanoparticles. Anti-tumor efficacy has been 
demonstrated in a murine model of mammary carcinoma, wherein IL-12 microsphere 
treatment was found to result in NK cell mediated anti-tumor effects (52). Combination 
therapy involving IL-12 and TNF receptor microspheres was found to lead to superior 
anti-tumor function with the recruitment of CD8+ T cells. Additional studies of IL-12 
microsphere treatment utilized a combination of IL-12 and GM-CSF, which mediated 
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regression of lung alveolar carcinomas in a murine model (38, 53). This study reported IL-12 
mediated effects including reactivation of tumor resident T cells as well as predicted 
apoptosis of regulatory T cells. The anti-tumor efficacy of polymer-mediated IL-12 delivery 
has also been tested in murine models of malignant glioma and disseminated ovarian cancer 
(54, 55). These studies validate the nanoparticle mediated delivery approach, demonstrating 
a sustained release and therapeutic efficacy, whilst contributing to the understanding of the 
mechanisms of IL-12 mediated anti-tumor efficacy. 
As an alternative approach to systemic infusion of IL-12, specific delivery of IL-12 directly 
into the tumor site may be achieved through gene therapy strategies. One such approach 
utilizes adenoviral vector mediated delivery of the IL-12 gene with subsequent expression 
and secretion of IL-12 by the infected cell. In this manner, direct intra-tumoral injection of 
adenovirus encoding the IL-12 gene resulted in anti-tumor responses in murine models of 
melanoma, laryngeal squamous cell carcinoma, glioma, renal cell carcinoma and bladder 
cancer (40, 56-59). Other models utilizing combinations of adenovirus and other 
chemotherapies have also demonstrated encouraging results. It was shown that a 
combination of cyclophosphamide and intra-tumoral injection of adenoviral gene transfer of 
IL-12 resulted in tumor eradication in a murine model of colorectal cancer (60). Additional 
strategies to further improve the safety of this response involve the utilization of organ 
specific, drug inducible adenoviral vectors. One study reported the use of a liver-specific, 
mifepristone-inducible adenoviral vector encoding IL-12 for the treatment of colorectal 
cancer liver metastasis (61). This system allowed for controlled and long term expression of 
the vector following systemic infusion, and was enhanced by additional treatment with the 
chemotherapeutic agent oxaliplatin (62). Other strategies testing drug inducible IL-12 
expression have yielded similar results, confirming the ability to tightly control IL-12 
production in vivo (63). 
Additional viral vector based strategies include the utilization of other oncolytic viruses, 
which preferentially infect and lyse tumor cells. Intra-tumoral injection of a vesicular 
stomatitis virus carrying an IL-12 transgene was demonstrated to reduce tumor volume in a 
murine model of squamous cell carcinoma (64). This reduction in tumor volume correlated 
to an increased survival of treated tumor bearing mice.  
Other delivery strategies include electroporation, where a voltage is applied to a cell 
membrane, allowing entry of plasmid DNA into a cell. To achieve this in vivo, studies have 
injected plasmids encoding the IL-12 gene intra-tumorally, followed by in vivo 
electroporation to allow for the introduction and expression of the gene into and by the 
regional cells (65). Utilizing a murine model of melanoma, it was found that electroporation 
of the IL-12 gene into the tumor resulted in tumor eradication in 47% of mice (65). This 
study also demonstrated the ability of IL-12 to stimulate an endogenous anti-tumor immune 
response as surviving mice were resistant to tumor re-challenge. Therapy resulted in 
increased levels of IL-12 and IFN in the tumor, increased lymphocyte infiltration and 
reduction in vascularity. These findings are consistent with previously documented effects 
of IL-12. This approach has similarly been successfully applied to a murine model of 
fibrosarcoma (66). 
Other novel strategies to target IL-12 to the tumor site include anchoring IL-12 to a tumor-
specific protein. One group utilized a single chain variable fragment (scFv) from an 
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antibody specific to erbB2 anchored to IL-12 to specifically deliver IL-12 to erbB2+ murine 
bladder cancers (67). This approach resulted in increased survival but failed to completely 
eradicate established disease. Similarly, investigators linked a IL-13R3 protein to IL-12 as a 
means of targeting murine melanoma (68). This group chose IL-13R3 as it can be a negative 
regulator of tumors that utilize IL-13 as a pro-tumorigenic factor. This therapy led to a 
significant NK T cell mediated inhibition of tumor growth in vivo.  
Indeed, combinations of these treatment modalities have also yielded encouraging results in 
preclinical testing. Intra-tumoral injection of adenovirus encoding IL-12 and 4-1BBL 
combined with DC injection was found to mediate marked inhibition of tumor growth in a 
murine model of melanoma (69). Another study demonstrated the intra-tumoral injection of 
IL-12 encoding plasmid followed by DC vaccination led to the suppression of primary 
hepatocellular carcinoma and metastases (70). Significantly, utilization of this combined 
immune based therapy approach to augment surgical resection of primary tumor yielded 
superior results, leading to long term survival and resistance to tumor re-challenge in 
murine models of ovarian cancer, prostate cancer and hepatocellular carcinoma (51); (71); 
(72). Combination of IL-12 gene therapy with IL-27 gene therapy, or retinoic acid based 
therapies have also been described, with encouraging responses against systemic tumors 
(73, 74). 
5. Clinical trials: Toxicity tempers the potential of IL-12 as an anti-cancer 
agent 
Previous pre-clinical studies demonstrating the anti-tumor efficacy of IL-12 warranted the 
translation of this therapeutic agent to the clinical setting. A number of tumors were 
targeted in these trials, with modest, mixed responses. The first published trial of 
systemically administered IL-12 was a phase I dose escalation trial of intravenous (i.v.) 
administered recombinant human interleukin 12 (rhIL-12) (75). Cohorts of four to six 
patients with advanced solid tumor malignancies received escalating doses (3-1000 
ng/kg/day) of rhIL-12 by bolus i.v. injection once and then, after a 2-week rest period, once 
daily for five days every 3 weeks. Forty patients were enrolled on this study including 20 
with renal cell carcinomas, 12 with melanoma, and 5 with colon cancer. One melanoma 
patient experienced a complete regression of metastatic disease for a period of four weeks, 
while a second patient with renal cell carcinoma experienced a partial response that was 
ongoing at 22 months. Toxicities observed in this trial were fever, chills, fatigue, nausea, 
vomiting, and headache. Routine laboratory findings reported abnormalities including 
anemia, neutropenia, lymphopenia, hyperglycemia, thrombocytopenia, and 
hypoalbuminemia. Dose limiting toxicities included oral stomatitis and elevated 
transaminases. The maximum tolerated dose (MTD) (500 ng/kg) was associated with 
asymptomatic hepatic function test abnormalities in three patients and one on study death 
due to Clostridia perfringens septicemia. Lymphopenia was observed at all dose levels, with 
recovery occurring within several days of completing treatment without rebound 
lymphocytosis (75). These adverse events were hypothesized to be related to administration 
of recombinant human IL-12 and so the immune effects of this therapy were interrogated. 
Consistent with pre-clinical data, IL-12 was shown to up-regulate IFN, in a dose-dependent 
fashion. Additionally, a single 500 ng/kg dose of rhIL-12 was shown to increase NK cell 
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cytolytic activity and T cell proliferation, as determined by studies on peripheral blood 
samples collected pre and post treatment (76). In a subsequent Phase II study of 17 patients 
investigators observed unexpected toxicities related to the dosing schedule of IL-12 
administration (77). On this study, 12 out of 17 patients required hospitalization and two 
patients died. Two patients deaths occurred during the phase II study were determined to 
be related to IL-12 administration. Postmortem examination of these two patients showed 
hemorrhagic ulceration in the large intestine (patient 1) and necrotizing aspiration 
pheumonia and diffuse hemorrhagic colitis (patient 2). The constitutional, cardiac, renal, 
hematopoietic, hepatic and neurologic toxicities observed in the phase II were similar to 
those dose-limiting toxicities observed on phase I studies with IL-12. These toxicities 
resulted in the suspension of IL-12 trials by the Food and Drug Administration (FDA). 
Significantly, investigators subsequently determined that a single IL-12 infused loading dose 
given two weeks prior to consecutive treatments (as done in the initial trial) abrogated these 
observed toxicities. 
A subsequent study by Gollob and colleagues (78), the authors describe two patients with 
renal cell carcinoma treated with twice-weekly intravenous rhIL-12 during a phase I trial. A 
cycle of therapy lasted 6 weeks. The patients had grade 4 neutropenia and grade 3 hemolytic 
anemias. The severe neutropenia was associated with bone marrow agranulocytosis and a 
preponderance of large granular lymphocytes in the peripheral blood, whereas the 
hemolytic anemia was associated with splenomegaly. Both patients had stable disease 4 
months after the IL-12 treatment was stopped with persisted agranulocytosis and hemolytic 
anemia.  
Additionally, thirty-four patients with measurable metastatic, recurrent or inoperable 
cervical carcinoma were enrolled on phase I clinical trial to investigate the anti-tumor effect 
of i.v administrated IL-12 at 250 ng/kg daily up to 21 days. Over half of these patients had 
received prior cisplatin-based chemotherapy. The most common serious toxicities were 
hematologic or hepatic, and all were reversible. The median survival was 6.5 months. This 
was the first clinical trial to demonstrate induction of cell-mediated immune (CMI) 
responses to specific antigens (HPV16 E4, E6, and E7 peptides) following treatment with IL-
12 in women with cervical cancer. However, this improvement in immune response was not 
associated with enhanced objective response or survival (79). 
Pharmacokinetic advantages of intraperitoneal (i.p.) rhIL-12 infusion, tumor response to 
i.p. delivery of cytokines, as well as its potential anti-angiogenic effect provided the 
rationale for further evaluation of rhIL-12 in patients with refractory or relapsed ovarian 
or peritoneal carcinoma. In this study (80) rhIL-12 was administered to 29 previously 
treated patients with peritoneal carcinomatosis from Müllerian carcinomas, 
gastrointestinal tract carcinomas and peritoneal mesothelioma in a phase I trial. rhIL-12 
doses were dose escalated between patients from 3 to 600 ng/kg weekly up to 6 months. 
Three or more patients at each level received weekly i.p. injections of rhIL-12. Dose-
limiting toxicity (grade 3 elevated transaminase levels) occurred in 50% of treated patients 
at the 600 ng/kg dose. More frequent, but less severe, toxicities included fever, fatigue, 
abdominal pain, and nausea. Ten patients received 300 ng/kg with acceptable frequency 
and severity of side effects. Two patients (one with ovarian cancer and one with 
mesothelioma) had no remaining disease at laparoscopy. Eight patients had stable disease 
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and 19 patients had progressive disease. Cytokines including IL-1, IL-2, IL-10, TNF, 
and IFN were determined in serum and peritoneal fluid samples during therapy. 
Immunobiological effects included peritoneal tumor cell apoptosis, decreased tumor cell 
expression of BFGF and VEGF, elevated IFN levels and IP-10 transcripts in peritoneal 
exudate, and increased proportions of peritoneal CD3+ T cells relative to CD14+ 
monocytes (80). In a subsequent phase II trial thirty-four patients with ovarian carcinoma 
or primary peritoneal carcinoma were treated i.p. with rIL-12 (300 ng/kg weekly) (81). 12 
patients completed this second phase were evaluated for response. There were no 
treatment related deaths, peritonitis or significant catheter related complications. 
Toxicities included grade 4 neutropenia (1), grade 3 fatigue (4), headache (2), myalgia (2), 
non-neutropenic fever (1), drug fever (1), back pain (1), and dizziness (1). Two patients 
had stable disease (SD) and 9 had progressive disease (PD). The authors concluded that 
rIL-12 can safely be administered by i.p. scheduled to patients after first line 
chemotherapy for ovarian/peritoneal carcinoma. Future i.p. therapies with rhIL-12 will 
require better understanding and control of pleiotropic effects of IL-12 since proteins with 
potential for both anti-tumor (IFN, IP-10) and pro-tumor growth effects (VEGF, IL-8) 
were detected in this study (81).  
To avoid toxicities associated with systemic infusion of rIL-12, others have investigated 
subcutaneous administration of IL-12. Rook and colleagues initiated a phase I dose 
escalation trial of rhIL-12 treating 10 patients with cutaneous T-cell lymphoma (CTCL) with 
dose escalating regimens of subcutaneous (s.c.) 50, 100, or 300 ng/kg rhIL-12 twice weekly 
or intralesional injections for up to 24 weeks (82). Histological analysis of regressing skin 
lesions revealed increased numbers of CD8+ T cells. In contrast to systemic rIL-12 infusion, 
sq or intralesional rIL-12 regimens were well tolerated with adverse effects limited to low-
grade fevers and headaches.  
Similarly, in another phase I trial, 28 patients with advanced renal cell carcinoma were 
treated s.c. with rhIL-12 that was administered on day 1 and followed on day 8 with 
repeated s.c. injections 3 times a week for 2 weeks. The MTD of the initial injection was 
evaluated at dose levels of 0.1, 0.5, and 1.0 g/kg. A dose limiting toxicity (DLT) was 
observed at 1.0 g/kg consisting of fever, perivasculitis of the skin, and leukopenia. Other 
notable toxicities were oral mucositis and transaminitis. These toxicities were more severe 
after the initial injection than after repeated injections at the same dose level. In this study, 
one patient had a partial response and seven patients had stable disease (83).  
The efficacy of s.c. rhIL-12 for the treatment of patients with early mycosis fungoides (MF; 
stage IA-IIA) has similarly been tested in a phase I clinical trial. In this study rhIL-12 was 
administered subcutaneously biweekly (100 ng/kg for 2 weeks; 300 ng/kg thereafter). 
Ten of 23 patients (43%) achieved partial responses (PR); 7 (30%) achieved minor 
responses; and 5 (22%) had stable disease. The duration of PRs ranged from 3 to more 
than 45 weeks. Twelve patients (52%) ultimately progressed with a mean time to 
progression of 57 days (range, 28-805). Seventeen patients had treatment-related adverse 
events that were generally mild to moderate in severity including asthenia, headache, 
chills, fever, injection site reaction, pain, myalgia, arthralgia, transaminitis, anorexia, and 
sweating. One patient in PR died of hemolytic anemia, possibly exacerbated by rhIL-12 
treatment (84).  
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Little and colleagues conducted phase II clinical trial wherein 36 patients with AIDS-
associated Kaposi sarcoma requiring chemotherapy were treated with six 3-week cycles of 
pegylated liposomal doxorubicin (20 mg/m2) plus interleukin-12 (300 ng/kg 
subcutaneously twice weekly), followed by 500 ng/kg subcutaneous IL-12 twice weekly for 
up to 3 years (85). Thirty patients had a major response, including 9 with a complete 
response, with an 83% overall response rate. Patients had elevated levels of IFN and IP-10 
in their serum, indicative of an rIL-12 mediated immune response.  
Finally, 42 previously treated patients (32 patients with relapsed or refractory non-
Hodgkin's lymphoma (NHL) and 10 patients with relapsed Hodgkin's disease (HD)) were 
enrolled in a phase II clinical trial to evaluate the clinical activity and toxicity of rIL-12. 
Patients were treated with either intravenous (n = 11) or subcutaneous (n = 31) rIL-12. The 
patients had received a median of three prior treatment regimens, and 16 patients had 
undergone prior autologous stem cell transplantation. All patients were assessable for 
toxicity, and 39 of 42 (93%) patients were assessable for response. Six of 29 (21%) patients 
with NHL had a partial or complete response, whereas none of the 10 patients with HD 
responded to rIL-12 therapy. Furthermore, 15 patients had stable disease that lasted for up 
to 54 months. The most common toxicity was flu-like symptoms. Reversible grade 3 hepatic 
toxicity was observed in three patients requiring dose reduction (86). This study 
demonstrated increased numbers of peripheral blood CD8+ T cells as well as decreased 
VEGF and BFGF in 37% of the treated patients indicative of a rIL-12 mediated immune 
response.  
Additional methods of delivering IL-12 to the tumor site have been investigated. Ten 
previously untreated patients with head and neck squamous cell carcinomas (HNSCC) 
received direct injection of rhIL-12 in the primary tumor weekly, at two dose levels of 100 or 
300 ng/kg, as neoadjuvant therapy prior to surgical resection. In this trial the histologic and 
immunohistopathologic effects of intratumorally (i.t) infused rhIL-12 were evaluated in the 
primary tumors and regional lymph nodes. In the primary tumor, the number of CD56+ NK 
cells was increased in rhIL-12-treated patients compared with control non-rhIL-12 treated 
patients. After i.t. rhIL-12 treatment of HNSCC patients, significant effects were noted on B 
cells, with altered lymph node architecture in every IL-12-treated patient and excessive 
peritumoral infiltration of B cells in some patients (87, 88). 
In a phase I/II clinical trial (89), plasmid DNA encoding human IL-12 was produced under 
good manufacturing practice (GMP) conditions and injected into lesions of nine patients 
with stage IV malignant melanoma previously treated with both standard and salvage 
chemotherapy regimens. Plasmid DNA was injected in cycles, three injections per cycle, for 
up to seven cycles. One cycle consisted of three injections at weekly interval, that is, on day 
1, 8 and 15, followed by a resting period of about 8 days (89). Local injection site anti-tumor 
responses were seen in a majority of patients, with four patients exhibiting responses at 
distant metastases and a complete remission was achieved in one patient. Biopsies of lesions 
from responding patients demonstrated a predicted increase in IL-12, IFN and IP-10 
expression analyzed by real-time polymerase chain reaction. 
In a similar study, nine patients with metastatic melanoma were treated by intra-tumoral 
injection of a recombinant viral vector expressing human IL-12 derived from the canarypox 
virus (ALVAC-IL-12). Increases in IL-12 and IFN mRNA, were observed in ALVAC-IL-12-
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injected tumors compared with saline-injected control tumors in four of the nine patients. 
ALVAC-IL-12-injected tumors were also characterized by increased T cell infiltration of the 
tumor (90). This therapy was well tolerated with no reported dose limiting toxicities. One 
patient achieved a complete response in the injected subcutaneous metastasis, but all 
patients developed neutralizing IgG antibodies to the viral vector, demonstrating a 
limitation to this viral delivery strategy.  
Viral vectors, probably the most commonly used for gene delivery, often result in host 
immune response, systemic toxicity and integration into host genome. Plasmid DNA-based 
vectors avoid these problems but are lacking in efficient gene transfer efficiency. In vivo 
electroporation, which utilizes an electric charge to facilitate entry of macromolecules into 
the cell, can be a reproducible and highly efficient method to deliver plasmid DNA. A phase 
I dose escalation trial of plasmid IL-12 gene electroporation was studied in patients with 
metastatic melanoma. Patients received electroporation treatments on days 1, 5, and 8 
during a single 39-day cycle, into metastatic melanoma lesions through a penetrating six-
electrode array immediately after DNA injection. A sterile applicator containing six needle 
electrodes arranged in the circle was inserted into the tumor and six pulses at field strength 
of 1,300 Volts/cm and pulse duration of 100 s were applied using a Medpulser DNA EPT 
System Generator. Twenty-four patients were treated at seven dose levels, with minimal 
systemic toxicity. Transient pain after electroporation was the primary adverse effect. Post-
treatment biopsies showed plasmid dose proportional increases in IL-12 levels as well as 
marked tumor necrosis and increased lymphocytic infiltrate. Two of 19 patients with 
nonelectroporated distant lesions and no other systemic therapy showed complete 
regression of all metastases, whereas eight additional patients (42%) showed disease 
stabilization or partial responses (91). 
A phase I trial to assess the safety and tolerability of i.p. injected human IL-12 plasmid 
(phIL-12) formulated with a synthetic lipopolymer, polyethyleneglycol-polyethyleneimine-
cholesterol (PPC), was conducted in women with chemotherapy-resistant recurrent ovarian 
cancer. A total of 13 patients were enrolled in four dose-escalating cohorts and treated with 
0.6, 3, 12 or 24 mg/m2 of the formulated plasmid once every week for 4 weeks (92). This 
approach is attractive because of the ability of nanoparticles to transport larger amounts of 
genetic material than viral vectors, as well as the ability of this approach to bypass the 
induction of an endogenous immune response as is the case with viral vectors (93). 
However, nanoparticles lack the specificity required to home to sites of tumor (92). 
Intraperitoneal administration of this IL-12 gene bearing nanoparticle was well-tolerated, 
with mild to moderate fevers and abdominal pain reported for each patient. Treatment was 
associated with stable disease and decrease in serum cancer antigen (CA)-125 by 3% in one 
of the three patients in cohort-1; 36 and 86% in two of three patients in cohort-2; and 2, 11 
and 16% in three of four patients in cohort-4 at the 5-week follow-up visit. There was an 
overall clinical response of 31% stable disease and 69% progressive disease at the 51 week 
post-treatment follow-up visits.  
At present, several additional trials utilizing IL-12 as an anti-cancer therapy are currently 
enrolling patients. Avigan and colleagues are recruiting patients for a phase I/II trials to 
evaluate co-administration of a dendritic cell/tumor fusion vaccine with subcutaneously 
administered IL-12 to patients with stage IV breast cancer (Avigan D., Vaccination of 
patients with breast cancer with dendritic cell/tumor fusions and IL-12, NCT00622401). 
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Gajewski and colleagues are investigating the role of multipeptide vaccination with or 
without an admixture of intradermally or subcutaneously delivered IL-12, with subsequent 
daclizumab therapy in patients with metastatic melanoma (Gajewski T.F., A randomized 
phase II study of multipeptide vaccination with or without IL-12, then combined with 
regulatory T cell depletion using daclizumab in patients with metastatic melanoma, 
NCT01307618). A group at the National Cancer Institute is conducting a clinical trial using a 
novel IL-12 agent in patients with treatment-refractory solid tumors. This trial is designed to 
test the safety and effectiveness of experimental drug NHS-IL12 as a treatment for solid 
tumors that have not responded to standard treatments. The NHS-IL12 immunocytokine is 
composed of 2 IL-12 heterodimers, each fused to one of the VH-chains of the NHS76 
antibody, which has affinity for both single- and double-stranded DNA. Thus, NHS-IL12 
targets delivery to regions of tumor necrosis where DNA has become exposed 
(NCT01417546). Other phase I/II study of metastatic melanoma will be conducted by 
Rosenberg group at NCI using lymphodepleting conditioning followed by infusion of tumor 
infiltrating lymphocytes genetically modified to express IL-12 (NCT01236573) (see below). 
These ongoing clinical trials convey the potential of this powerful immune stimulatory 
cytokine, while highlighting the necessity for careful dosing and more importantly, targeted 
delivery to reduce the risks of toxicity. 
6. The promise of adoptive cell immunotherapy 
Adoptive cell therapy involves the isolation, modification and expansion of endogenous 
immune cells, followed by the ex vivo expansion of and re-infusion of these cells into a 
tumor-bearing host. Indeed, the use of cells to deliver IL-12 to a tumor is attractive as 
natural immune cell features can be exploited whilst delivering IL-12 to the tumor 
microenvironment. One such example of this approach is the utilization of mesenchymal 
stem cells (MSCs) to deliver IL-12. MSCs have a widely reported ability to traffic to sites of 
tumor growth making them ideal delivery for IL-12 (94). Several groups have reported the 
use of MSCs to deliver IL-12 to tumors in murine models of glioma, renal cell carcinoma, 
breast cancer, melanoma, Ewing sarcoma and prostate cancer (95-99). These studies 
demonstrate that MSCs are successful delivery vehicles of IL-12 and the IL-12 delivered 
mediates anti-tumor responses in preclinical murine models involving increased IFN, 
increased infiltration of T cells and anti-angiogenic effects (95). 
Antigen presenting cells (APCs) can also be utilized in cell transfer therapy. Although APCs 
have the endogenous capacity to produce IL-12, the hostile tumor microenvironment often 
suppresses this immune stimulatory response. Adoptive transfer of APCs genetically 
modified to continually produce IL-12 is aimed at initiating an endogenous anti-tumor 
immune response. The most commonly utilized APCs for IL-12 delivery are DCs. 
Intratumoral injection of DCs modified to express IL-12 mediated complete regression of 
neuroblastoma tumor in a mouse model (100). This effect was shown to correlate with 
increased tumor-specific splenocyte cytoxic capacity. Other groups have tested this 
approach in murine liver tumor models with similar encouraging responses (101). This latter 
study specifically demonstrated the generation of a protective immune response, which was 
dependent on T and NK cells. One alteration of this approach involves the pulsing of the IL-
12 modified DCs with tumor lysates to increase the immune-stimulatory capacity of the 
injected cells. Using a model of colon cancer, mice were treated with tumor lysate pulsed, 
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IL-12 gene modified DCs which was found to dramatically inhibit tumor growth (102). This 
therapy resulted in an increase of endogenous immune tumor specific cytotoxicity and 
increased IFN levels, consistent with previously reported effects of IL-12. Injection of IL-12 
gene modified macrophages was also found to inhibit tumor growth and spontaneous 
metastasis following prostatectomy in a murine model of prostate cancer (71). These studies 
support the utilization of APC mediated delivery of IL-12 to the tumor microenvironment as 
a method to initiate an effective endogenous anti-tumor response.  
Other immune cells employed in adoptive transfer anti-cancer therapy include adaptive 
immune effector cells. Cytokine induced killer (CIK) cells are generation by the ex vivo 
activation and expansion of T cells, resulting in a cell population with both T and NK cell 
phenotypes (103). Using a preclinical, immunocompetent murine model of breast cancer, it 
was shown that augmentation of CIK therapy with IL-12 resulted in enhanced anti-tumor 
efficacy and complete remission in 75% of mice following therapy (104). This was found to 
be due to IL-12-mediated increased immune mediated cytotoxicity, improved homing and 
persistence, as well as in vivo proliferation of transferred CIK cells. 
A similar strategy to deliver IL-12 specifically to tumor cells involves the use of tumor-
specific T cells (50, 105). In an initial report, transgenic mouse T cells specific for the gp100 
melanoma antigen were genetically modified to express an IL-12 transgene (105). These cells 
were then infused into irradiated mice bearing subcutaneous melanoma tumors. It was 
found that these IL-12 producing targeted T cells mediated rejection of tumor with dose 
responsive toxicity. When lower numbers of T cells were transferred into these mice, toxicity 
was absent and anti-tumor effects still eradicated advanced tumors, though effective 
therapy still required prior lymphodepletion. These anti-tumor effects were dependent on 
the IL-12 being present in the tumor microenvironment as T cells cultured ex vivo in IL-12 
did not have similar anti-tumor activity. Consistent with previously published results, 
therapy was associated with CD8+ T and NK cell infiltration and a reduction of Foxp3 
expression within the tumor. To further improve the safety of this approach, an additional 
study reported control of IL-12 expression by a promoter containing binding sites for 
nuclear factor of activated T cells (NFAT) resulting in IL-12 production only upon T cell 
activation within the targeted tumor microenvironment (106). An additional report 
describes the isolation of murine T cells, genetically engineered ex vivo to express the IL-12 
transgene and a chimeric antigen receptor (CAR) targeted to the carcinoembryonic antigen 
expressed on colon cancers (50). This study demonstrated the translational applicability of 
this approach, and a novel potentially clinically applicable approach to tumor targeted 
delivery of the IL-12 cytokine. This approach is currently being investigated in a clinical 
trial, as described to above. Rosenberg and colleagues are currently enrolling patients in a 
trial utilizing ex vivo expanded tumor-infiltrating lymphocytes modified to produce IL-12 
for the treatment of metastatic melanoma (NCT1236573).  
7. Conclusion 
IL-12 is a potent mediator of anti-tumor immunity. The exact mechanisms of IL-12 mediated 
anti-tumor effects continue to warrant further investigation. While translation to the clinical 
setting has been hampered by toxicity and modest anti-tumor efficacy, localized delivery of 
IL-12 directly into the tumor may prove to be a successful approach in limited numbers of 
accessible tumors. However, it is perhaps in the setting of adoptive T cell immunotherapy 
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utilizing IL-12 secreting, tumor specific T cells, where the full anti-tumor benefit of IL-12 
therapy will be realized with tumor targeted, locally secreted cytokine. This approach will 
avert systemic toxicity while providing the requisite boost to the endogenous immune 
system to fully eradicate tumor. IL-12 remains a unique and promising cytokine with 
marked anti-tumor activity and warrants continued rigorous investigation in both the pre-
clinical and clinical settings in order to realize the full anti-tumor potential of this reagent. 
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